Conference item
Overexpression of heme oxygenase-1 protects allogeneic thyroid grafts from rejection in naive mice.
- Abstract:
- BACKGROUND: Endocrine allografts are an option for the treatment of endocrine failure. METHODS: One lobe of the thyroid was transplanted under the kidney capsule. RESULTS: C57BL/10 (H2(b)) thyroids were rejected in naive CBA (H2(k)) mice within 14 days after transplantation. When mice were treated with anti-CD4 monoclonal antibodies (mAb), all grafts survived for more than 60 days. The first grafts still survived after second C57BL/10 or Balb/c (H2(d)) thyroid grafts that were transplanted into the same recipients were rejected acutely, which suggests that the primary grafts were modified under anti-CD4 mAb treatment. To confirm this hypothesis, C57BL/10 thyroid grafts from anti-CD4 mAb-treated mice were retransplanted. All grafts survived in naive mice; this correlated with the overexpression of heme oxygenase-1 (HO-1) in the grafts. Next, an inhibitor of HO-1 (zinc protoporphyrin) or control compound (copper protoporphyrin) was injected intraperitoneally after transplantation of C57BL/10 thyroid grafts into the primary CBA recipients that had been treated with anti-CD4 mAb. The grafts in mice that had been treated with zinc protoporphyrin, but not copper protoporphyrin, were rejected when retransplanted to naive recipients. CONCLUSIONS: Overexpression of HO-1 correlated with the protection of fully allogeneic thyroid grafts from rejection when retransplanted into naive recipients.
- Publication status:
- Published
Actions
Authors
- Host title:
- Surgery
- Volume:
- 128
- Issue:
- 6
- Pages:
- 910-917
- Publication date:
- 2000-12-01
- Event location:
- UNITED STATES
- DOI:
- EISSN:
-
1532-7361
- ISSN:
-
0039-6060
- Keywords:
- Pubs id:
-
pubs:136041
- UUID:
-
uuid:550644a2-b5f5-46e9-a209-a4fe015bfe95
- Local pid:
-
pubs:136041
- Source identifiers:
-
136041
- Deposit date:
-
2012-12-19
Terms of use
- Copyright date:
- 2000
If you are the owner of this record, you can report an update to it here: Report update to this record